Detalhe da pesquisa
1.
Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Bioorg Med Chem Lett
; 27(3): 413-419, 2017 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28041831
2.
Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Bioorg Med Chem Lett
; 26(4): 1124-9, 2016 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26821821
3.
Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors.
Bioorg Med Chem Lett
; 26(12): 2855-2860, 2016 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27146606
4.
A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential.
Nat Commun
; 15(1): 274, 2024 Jan 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38177138
5.
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Bioorg Med Chem Lett
; 22(23): 7100-5, 2012 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23089526
6.
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.
Endocrinology
; 148(11): 5175-85, 2007 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-17656463
7.
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
J Endocrinol
; 192(2): 371-80, 2007 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-17283237
8.
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Nat Med
; 23(9): 1086-1094, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28825717
9.
Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal.
J Med Chem
; 49(25): 7545-8, 2006 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-17149884
10.
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
PLoS One
; 9(5): e97139, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24858947
11.
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
J Med Chem
; 55(3): 1318-33, 2012 Feb 09.
Artigo
Inglês
| MEDLINE | ID: mdl-22196621
12.
PDE-10A inhibitors as insulin secretagogues.
Bioorg Med Chem Lett
; 17(10): 2869-73, 2007 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17400452